| Literature DB >> 33681730 |
Mohammad Rashidul Hashan1,2, Nicolas Smoll2, Catherine King3,4, Hannah Ockenden-Muldoon2, Jacina Walker2, Andre Wattiaux5, Julieanne Graham6, Robert Booy3,4, Gulam Khandaker1,2,4.
Abstract
BACKGROUND: COVID-19 outbreaks in aged care facilities (ACFs) often have devastating consequences. However, epidemiologically these outbreaks are not well defined. We aimed to define such outbreaks in ACFs by systematically reviewing literature published during the current COVID-19 pandemic.Entities:
Keywords: Aged care facility; Clinical features; Coronavirus disease 2019; Covid-19; Epidemiology; Nursing homes; Outbreak; SARS-CoV-2
Year: 2021 PMID: 33681730 PMCID: PMC7917447 DOI: 10.1016/j.eclinm.2021.100771
Source DB: PubMed Journal: EClinicalMedicine ISSN: 2589-5370
Fig. 1Flow diagram of the study selection process.
Fig. 2Global distribution of the included studies by country.
Characteristics of included studies and epidemiologic index of SARS-CoV-2 in aged care facilities.
| First Author/ Year | Country | Study design | Study period (month) | Outbreak setting (number of facilities) | Number of outbreak | Participants investigated in the facility | Index case | Total number of residents | Total number of investigated participants (N)⁕ | RT-PCR-confirmed COVID-19 cases (n)⁕ | Sex distribution of COVID-19 cases (M/F)¶ | Age of COVID-19 residents (years)¥ | Attack rate (%) | Case fatality rate (%) | Mortality rate (%) | Fidelity of reporting |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Gilbert/202030 | Australia | Case study | March | NH (1) | 1 | R, S | Staff, Female | 76 | 76 | 17 | NR | NR | 22.·3 | 35·2 | 7·8 | HF |
| Frank/202029 | Belgium | Retrospective cohort | March–April | NH (1) | 1 | R, S | NR | 130 | 118 | 40 | NR | NR | 30.·7 | NR | NR | HF |
| Stall/202023 | Canada | Retrospective cohort | March–May | LTC (190) | 190 | R | NR | 22,990 | NR | 5218 | NR | NR | 22·6 | 27·8 | 6·3 | LF |
| Stall/202022 | Canada | Retrospective cohort | April | NH (1) | 1 | R, S | NR | 126 | 126 | 89 | NR | NR | 70·6 | 13·4 | 9·5 | LF |
| Hu/202031 | China | Retrospective cohort | January–April | NH (1) | NA | R | NR | 34 | 34 | 34 | 11/23 | 82·7 (7·4) | NR | NR | NR | LF |
| Blain/202024 | France | Prospective cohort | March | NH (1) | 1 | R, HCP | NR | 79 | 79 | 38 | NR | 86 | 48·1 | 31·5 | 15·1 | HF |
| Belmin/ 202025 | France | Retrospective cohort | March–May | NH (17) | NA | R, S | Resident | 1250 | 1250 | 5 | NR | NR | 0·4 | 100 | 0·4 | LF |
| Sacco/202026 | France | Retrospective cohort | March | NH (1) | NA | R, S | NR | 87 | 87 | 41 | 15/26 | 88·8 (7) | 47·1 | 26·8 | 12·6 | HF |
| Guery/202027 | France | Letter | April | NH (1) | 1 | S | Resident, Female, 80 years | NR | 136 | 3 | NR | NR | NR | 2·2 | NR | HF |
| Klein/202028 | Germany | Prospective cohort | March | NH (1) | 1 | R | NR | 60 | 60 | 39 | NR | NR | 65 | 20·5 | 13·3 | HF |
| Kennelly/ 202032 | Ireland | Cross-sectional | April–May | NH (28) | 21 | R, S | NR | 1741 | 1741 | 710 | NR | NR | 40·8 | 25·8 | 10·5 | HF |
| Nouvenne/ 202033 | Italy | Prospective cohort | April | NH (5) | NA | R | NR | 83 | 83 | 44 | NR | NR | 53·0 | NR | NR | LF |
| Veronese/ 202034 | Italy | Retrospective cohort | April–May | NH (1)` | NA | R | NR | 175 | 175 | 50 | NR | NR | 28·5 | 24·0 | 6·9 | HF |
| Carta/202035 | Italy | Prospective cohort | March–April | LTCF (1) | NA | R | NR | 65 | 65 | 54 | 35/8 | 81 (56–97) | 83·0 | 20·3 | 16·9 | LF |
| Rutten/ 202036 | Netherlands | Prospective cohort | March–April | NH (1) | NA | R | NR | 1969 | 1969 | 857 | 300/557 | 84 (8·7) | 43·5 | NR | NR | LF |
| Van Den Besselaar/ 202037 | Netherlands | Retrospective cohort | May–June | NH (1) | 1 | R, S | NR | 181 | 181 | 113 | 31/82 | 85 [44–99] | NR | 62·4 | NR | HF |
| Van Buul/202038 | Netherland | Cross-sectional | May | NH (3) | NA | R, HCP | NR | 297 | 297 | 16 | NR | NR | NR | 5·3 | NR | HF |
| Kittang/ 202039 | Norway | Retrospective cohort | March–April | NH (3) | 3 | R, S | Pre-symptomatic staff, Resident | 115 | 115 | 40 | 14/26 | 86·2 (69–98) | 34·7 | 52·5 | 18·2 | HF |
| Park/202040 | Republic of Korea | Prospective cohort | April | LTCF (3) | 3 | R, S | Caregiver, Female, 45 years; Resident, Female, 50 & 85 years | 569 | 266 | 18 | 68/109 | 82·4 | 3·1 | 38·9 | 1·2 | HF |
| Song/202041 | Republic of Korea | Cross-sectional | May | NF (5) | 5 | R, S | Daytime worker, Resident | 296 | 137 | 41 | NR | NR | 13·8 | 14·6 | 2·0 | HF |
| Borras-Bermejo/202042 | Spain | Cross-sectional | April | NH (69) | 1 | R, S | NR | 3214 | 3214 | 768 | NR | NR | 23·8 | NR | NR | LF |
| Bearnabeu-Wittel/202068 | Spain | Retrospective cohort | March–April | NH (4) | 4 | R | NR | 457 | 457 | 272 | 67/205 | 87 [81–91] | 59·5 | 22·4 | 13·3 | HF |
| Ladhani/202044 | UK | Prospective cohort | April | NH (6) | 6 | R, S | NR | 264 | 264 | 105 | 23/82 | 88 [85–91] | 39·7 | 16·1 | 3·2 | HF |
| Graham/202045 | UK | Prospective cohort | March–April | NH (4) | 4 | R, S | Resident€ | 394 | 313 | 126 | NR | NR | 31·9 | 16·7 | 5·3 | HF |
| Marossy/202046 | UK | Cross-sectional | May | ECH (6), NH (18), RF (13) | 37 | R, S | NR | 1034 | 1034 | 93 | 22/71 | 88·1 | 8·9 | 36·5 | 3·2 | LF |
| Shallcross/202047 | UK | Cross-sectional | April–June | LTC (2724) | 2724 | R, S | NR | 160,033 | 113,160 | 12,995 | NR | NR | NR | 8·1 | NR | LF |
| Smith/202048 | UK | Prospective cohort | April–June | ECH (44) | 14 | R, S | NR | 518 | 518 | 103 | 41/62 | 87·8 (71–104) | 19·8 | 20·3 | 4·0 | HF |
| McMiachael/202011 | USA | Retrospective cohort | March | SNF (1) | 1 | R, HCP, V | Resident, Female, 73 years | 130 | 118 | 101 | 32/69 | 83 (51–−100) | 77·7 | 33·7 | 26·1 | HF |
| Roxby/202012 | USA | Prospective cohort | March | Independent/ALF (1) | 1 | R, S | NR | 80 | 80 | 4 | NR | NR | 5 | NR | NR | HF |
| Patel/202049 | USA | Prospective cohort | March | SNF (1) | 1 | R, S | Resident, Female, 57 years | 127 | 126 | 35 | 11/24 | 82 [75–92] | 16·2 | 28·5 | 7·8 | HF |
| Temkin-Greener/202050 | USA | Retrospective cohort | March–May | ALF (4685) | NA | R | NR | NR | NR | 2647 | NR | NR | NR | 29·3 | NR | LF |
| Weil/202051 | USA | Cross-sectional | March–May | SNF (15), ALF (1) | NA | R, S | NR | 1208 | 1208 | 110 | NR | NR | 9·1 | NR | NR | LF |
| Sanchez/202052 | USA | Cross-sectional | March–May | SNF (26) | NA | R | NR | 2773 | 2773 | 1207 | NR | 72 [64–82] | 43·5 | 23·7 | 10·3 | HF |
| Louie/202053 | USA | Prospective cohort | March–April | SNF (3), ALF (1) | 4 | R, HCP | NR | 156 | 156 | 63 | NR | NR | 40·3 | 19 | 7·6 | HF |
| Arons/202013 | USA | Cross-sectional | March | SNF (1) | 1 | R, S | NR | 89 | 76 | 48 | NR | 78.6 (9·5) | 53·9 | NR | NR | HF |
| Goldberg/202054 | USA | Cross-sectional | April | SNF (1) | 1 | R, S | NR | 97 | 97 | 83 | NR | NR | 85·5 | 28·9 | 24·7 | HF |
| Dora/202055 | USA | Prospective cohort | March–April | SNF (1) | NA | R, S | Resident, Male, > 90 years | 99 | 99 | 19 | 19/0 | 75 [66–85] | 19·1 | 5·2 | 1·0 | HF |
| Bigelow/202056 | USA | Prospective cohort | April | NH (1) | 1 | R | NR | 170 | 170 | 37 | NR | NR | 21·7 | NR | NR | HF |
| Feaster/202057 | USA | Prospective cohort | April | SNF (8), ALF (1) | NA | R, S | NR | 608 | 582 | 408 | 171/237 | 78·4 (13) | 67·1 | NR | NR | HF |
| Mills/202058 | USA | Prospective cohort | April | ALF (101) | 3 | R | NR | 1794 | 35 | 7 | 2/5 | 81·9 (11) | 0·03 | 14·2 | 0·05 | LF |
| Harris/202059 | USA | Prospective cohort | April | SNF (1) | 1 | R | NR | 48 | 48 | 41 | NR | NR | 85·4 | 14·6 | 12·5 | HF |
| Shrader/202060 | USA | Prospective cohort | March | LTC (1) | 1 | R, S | Resident, Female, 72 years | 98 | 98 | 52 | NR | NR | 53·0 | 9·6 | 5·1 | HF |
| Jatt/202061 | USA | Prospective cohort | March–April | SNF (1) | NA | R | NR | NR | 149 | 18 | NR | NR | 12·0 | NR | NR | LF |
| Escobar/202062 | USA | Prospective cohort | April | NH (1) | 1 | R, S | Resident | 84 | 84 | 27 | NR | 86 (15.5) | 32 | NR | NR | HF |
| Rudolph/202063 | USA | Prospective cohort | April | CLC (134) | NA | R | NR | 7325 | 7325 | 443 | 432/11 | 76.3 (10·8) | 6·0 | NR | NR | HF |
| Eckardt/202064 | USA | Cross-sectional | April–May | LTC (1) | 1 | R, S | NR | NR | 276 | 10 | NR | NR | 3·6 | NR | NR | HF |
| Quicke/202065 | USA | Prospective cohort | NR | SNF (5) | 4 | S | NR | NR | 351 | 70 | NR | NR | 19·9 | NR | NR | LF |
| Telford/202066 | USA | Prospective cohort | March | SNF, NH, ALF (28) | 28 | R, S | NR | 2868 | 2868 | 821 | NR | NR | 28·6 | 16·2 | 4·5 | HF |
| Shi/202067 | USA | Retrospective cohort | March–May | LTC (1) | 1 | R | NR | 389 | 389 | 146 | 66/80 | 55·9 | 37·5 | 30·1 | 11·3 | HF |
R = resident, S = staff, HCP = healthcare professional, V = visitor, NR = not reported, NA = not applicable, NH = nursing home, SNF = skilled nursing facility, LTC = long-term care, ECH = extra-care home, ALF = assisted-living facility, RT-PCR = reverse transcriptase polymerase chain reaction, ¥ = age in years expressed in mean (SD), median [IQR], or mean (range) as reported. ⁕ = two data entries on the column, first refers to resident and second refers to staff, ¶ = male/female, €=only one facility reported the index case status. HF = high fidelity (studies that explicitly reported the total number of at-risk participants in the facility, total number of RT-PCR-confirmed cases, and number of individual participants tested during the study period separately). LF = low fidelity (studies missing any of the key denominators to estimate one of the principle summary measures). Attack rate expressed as percentage (%): (Number of positive cases/Total number of at-risk population) * 100; case fatality rate expressed as percentage (%): (Number of death cases/Total number of positive cases) * 100; mortality rate expressed as percentage (%): (Number of death cases/Total number of residents in the facility) * 100. All rates were calculated only for residents in the facility.
Rate of clinical manifestations, co-morbidity disorders, and outcomes amongst confirmed COVID-19 residents in aged care homes.
| Characteristics | Number of studies (N) | Confirmed cases (n/N) | Proportion (95% confidence interval) |
|---|---|---|---|
| 13 | 311/985 | 0·31 (0·28–0·34) | |
| 13 | 647/1019 | 0·65 (0·61–0·68) | |
| Typical symptoms | 4 | 74/247 | 0·30 (0·24–0·36) |
| Atypical symptoms | 5 | 82/989 | 0·08 (0·06–0·10) |
| Cough | 14 | 850/1876 | 0·45 (0·43–0·47) |
| Dyspnoea | 10 | 448/1497 | 0·29 (0·27–0·32) |
| Sore throat | 6 | 66/1128 | 0·05 (0·04–0·07) |
| Rhinorrhoea | 5 | 70/1331 | 0·05 (0·04–0·06) |
| Hypoxia | 5 | 126/373 | 0·33 (0·29–0·38) |
| Polypnea | 2 | 38/79 | 0·48 (0·37–0·59) |
| Fever | 13 | 935/1872 | 0·49 (0·47–0·52) |
| Hypothermia | 1 | 4/41 | 0·09 (0·03–0·23) |
| Weakness | 6 | 199/1421 | 0·14 (0·12–0·15) |
| Malaise | 5 | 88/1162 | 0·07 (0·06–0·09) |
| Anorexia | 9 | 250/1712 | 0·14 (0·13–0·16) |
| Myalgia | 5 | 8/256 | 0·03 (0·01–0·06) |
| Hypotension | 1 | 2/41 | 0·04 (0·01–0·17) |
| Chills | 3 | 5/196 | 0·02 (0·01–0·06) |
| Rash | 1 | 2/103 | 0·01 (0·00–0·07) |
| Conjunctivitis | 1 | 1/41 | 0·02 (0·00–0·01) |
| diarrhoea | 7 | 81/647 | 0·12 (0·10–0·15) |
| Nausea | 6 | 32/528 | 0·06 (0·04–0·08) |
| Vomiting | 6 | 56/1461 | 0·03 (0·03–0·04) |
| Acute gastrointestinal symptoms | 3 | 22/177 | 0·12 (0·08–0·18) |
| Ageusia | 1 | 4/272 | 0·01 (0·00–0·03) |
| Anosmia | 2 | 4/313 | 0·01 (0·00–0·02) |
| Headache | 7 | 45/1116 | 0·04 (0·03–0·05) |
| Confusion | 5 | 262/1174 | 0·22 (0·20–0·24) |
| Altered mental status | 1 | 4/41 | 0·09 (0·03–0·23) |
| Delirium | 5 | 150/607 | 0·24 (0·21–0·28) |
| Falls | 5 | 52/602 | 0·08 (0·06–0·11) |
| Dizziness | 2 | 5/89 | 0·05 (0·02–0·12) |
| Seizure | 1 | 1/35 | 0·02 (0·00–0·17) |
| Male | 18 | 1360/3037 | 0·44 (0·43–0·46) |
| Female | 18 | 1670/3037 | 0·55 (0·53–0·57) |
| Cardiac disease | 11 | 453/1251 | 0·36 (0·33–0·38) |
| Pulmonary disease | 12 | 303/1334 | 0·25 (0·22–0·27) |
| Hypertension | 7 | 662/993 | 0·66 (0·63–0·69) |
| Obesity | 9 | 181/833 | 0·21 (0·19–0·24) |
| Smoker | 2 | 19/67 | 0·28 (0·18–0·40) |
| Diabetes mellitus | 12 | 395/1292 | 0·33 (0·30–0·35) |
| Cancer | 3 | 26/168 | 0·15 (0·10–0·21) |
| Liver disease | 2 | 10/128 | 0·05 (0·02–0·09) |
| Renal disease | 9 | 165/536 | 0·30 (0·27–0·34) |
| Cerebrovascular disease | 5 | 127/512 | 0·24 (0·21–0·28) |
| Dementia | 5 | 550/821 | 0·67 (0·63–0·70) |
| Cognitive dysfunction | 3 | 165/201 | 0·82 (0·76–0·86) |
| Received haemodialysis | 2 | 4/75 | 0·05 (0·02–0·13) |
| dyslipidaemia | 3 | 148/340 | 0·43 (0·38–0·48) |
| neurological disorder | 2 | 67/299 | 0 |
| Anxiety disorder | 1 | 37/272 | 0·14 (0·10–0·18) |
| Depression | 1 | 72/272 | 0·26 (0·21–0·32) |
| Hospitalized | 12 | 1057/2829 | 0·37 (0·35–0·39) |
| ICU admission | Not reported | ||
| Invasive ventilation | Not reported | ||
= Studies explicitly reporting symptomatic and asymptomatic cases number were included in the analysis.
Fig. 3Forest plot of the attack rate of residents in aged care homes
Horizontal lines represent the 95% CIs around the point estimates for each study, and the grey shaded areas are proportional to the weight given to each study.
Fig. 4aForest plot of the case fatality rate of residents in aged care homes (all studies). Horizontal lines represent the 95% CIs around the point estimates for each study, and the grey shaded areas are proportional to the weight given to each study.
Fig. 4bForest plot of the case fatality rate of residents in aged care homes (single-centre studies). Horizontal lines represent the 95% CIs around the point estimates for each study, and the grey shaded areas are proportional to the weight given to each study.
Fig. 5Funnel plot of publication bias based on the pooled attack rate and case fatality rate. The upper-left funnel plot shows the publication bias for all studies; the upper-right funnel plot shows the bias for studies reporting outbreaks in a single centre; the middle-left funnel plot shows the bias for all studies reporting a case fatality rate; the middle-right funnel plot shows the bias for case fatality rates from single-centre outbreaks. the lower-left funnel plot shows the bias for all studies reporting mortality rate; the middle-right funnel plot shows the bias for mortality rates from single-centre outbreaks. Red diamond: large multi-facility reports; blue diamond: medium-sized multi-facility reports; black: single-centre reports. x-axis=proportion, y-axis=sampling variance.